Business Wire

VodafoneZiggo Relies on K2View to Power Combined Customer Repository

Share

K2View, a leading provider of real-time DataOps and data management solutions, today announced that it is powering VodafoneZiggo’s Combined Customer Repository (CCR) solution. In this capacity, K2View Fabric is delivering comprehensive customer and product data across VodafoneZiggo customers.

Achieving a comprehensive view of data across customers and products continues to be a challenge for virtually every organization. This challenge is caused by decades of data management best practices that have resulted in a diverse set of data sources, complicating data management. K2View Fabric takes a fundamentally different approach with the introduction of the patented Digital Entity – a person, place, or thing, recreated digitally out of its data.

“As we approached the merger of VodafoneZiggo, we needed to provide near real-time eligibility checks and initiate benefit provisioning to converged customers with both a fixed and mobile subscription. Before K2View, our legacy CCR led to the ongoing success of the merger; however, there were also some limitations,” said Marc Schmeetz, Program Manager, VodafoneZiggo. “Over time, this legacy CCR system had proven not to have the required flexibility or agility to support future Business demands; further, data updates that were occurring over a 24-hour period or longer were becoming an increasing worrying factor. Due to evolving customer expectations, this processing time window was no longer acceptable, and there was an additional risk when projects changed or added functionality in the previous CCR. To continue to provide excellent customer care, a change needed to be made. But with K2View, there’s no drama. We’ve gone from 24+ hours for updates to having data simply available in minutes or even seconds – we’re happy with how it is performing.”

With K2View powering the CCR, VodafoneZiggo can more easily implement new or changing rules due to their newly improved agility. As a result, the company has an accelerated ability to bring those changes to market.

“By simply enabling us to move with more agility, K2View is helping to open up new opportunities for VodafoneZiggo,” said Reinhard Kreft, IT Director, VodafoneZiggo. “If the improvements in our ability to go to market were not enough, the near real-time eligibility checks and provisioning of benefits boost the customer experience and support our customer care agents. We’re confident that K2View will be able to support our vision, especially as we turn towards building out a true and comprehensive ‘Customer 360’ view.”

About K2View

K2View is a leading provider of advanced data fabric, data integration, and data delivery software that takes the promise of a 360-degree view of data to the next level. Its flagship solution, K2View Fabric, uses patented logical unit technology to enable quick, easy, and secure access and control to all of an organization’s data, no matter how many different systems and data sources it may have. K2View delivers real-time, holistic access and operational insights to whatever data matters most to organizations in any industry, right when they need it, accelerating transformations in customer experience, cloud enablement, operations, IT modernization, and risk and compliance. Learn more at www.k2view.com and follow us at @k2view.

About VodafoneZiggo

VodafoneZiggo is a leading Dutch company that provides fixed, mobile, and integrated communication and entertainment services to consumers and businesses. As of March 31, 2020, VodafoneZiggo has more than 5 million mobile, nearly 4 million TV, nearly 3.4 million fixed broadband internet and 2.4 million fixed telephony subscriptions. VodafoneZiggo is a joint venture by Liberty Global, the largest international TV and broadband internet company, and Vodafone Group, one of the world’s largest telecommunication companies.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For more information on K2View, please contact:
Aaron Fullen
K2View
aaron.fullen@k2view.com

For further information on VodafoneZiggo, please contact:
Media Relations
VodafoneZiggo the Netherlands
pers@vodafoneziggo.com
0031 – 88 717 0717

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye